# Foghorn Therapeutics (FHTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/FHTX
## Company Profile
- Ticker: FHTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 1.97 USD
- Market cap: 213131536.85999998 USD
- Last updated: 2026-10-06
## Business Overview
Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets. Its platform seeks to create differentiated cancer therapies through epigenetic control.
## Why The Stock Is Moving

As of Oct 6, 2026, FHTX closed down 1.50% at $1.97. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Foghorn sits in specialty oncology biotechnology.

## Business Model

The company depends on translational data, target validation, and the possibility of building a new oncology platform.

## Landscape Position

Foghorn is a high-catalyst oncology name with strong dependence on early data quality.

## Future Catalysts

- Foghorn’s next three months are about its chromatin-regulation oncology programs and any data that show the platform can still produce differentiated human results. The market will care most about whether the synthetic-lethality thesis can keep moving forward.

## Recent News
- 2026-10-01 11:00 EST — [Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-update-on-fhd-909-and-strategic-priorities-0b277f05) — Source: Foghorn Therapeutics
- 2026-08-06 11:00 EST — [Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-second-quarter-2026-financial-and-corporate-update-7fd78e1f) — Source: Foghorn Therapeutics
- 2026-06-05 11:00 EST — [Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-heal-33b89134) — Source: Foghorn Therapeutics
- 2026-05-12 11:00 EST — [Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may) — Source: Foghorn Therapeutics
- 2026-05-07 11:00 EST — [Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update) — Source: Foghorn Therapeutics